Drugs and patents in ATC class N05AX

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
RISVAN	risperidone
RYKINDO	risperidone
PERSERIS KIT	risperidone
RISPERDAL CONSTA	risperidone
RISPERIDONE	risperidone
RISPERDAL	risperidone
UZEDY	risperidone
>Tradename	>Generic Name

Last updated: February 19, 2026

The market for N05AX antipsychotics is characterized by a mature patent landscape for several key agents, leading to increasing generic competition. While established blockbuster drugs are facing or have faced patent cliffs, the segment also shows continued innovation in the development of novel compounds with improved efficacy and side-effect profiles. Patent expirations for prominent N05AX drugs are creating significant opportunities for generic manufacturers, while ongoing patent filings indicate a pipeline of new chemical entities and formulation improvements.

What are the key N05AX antipsychotics with upcoming patent expirations?

The patent expiration timeline for several significant drugs within the N05AX class presents a clear trajectory for market shifts. These expirations are critical for generic manufacturers seeking to enter the market and for stakeholders evaluating investment opportunities.

Risperidone: The foundational patents for risperidone have long expired, leading to extensive generic availability. Its market share has been significantly impacted by generic entry, a process that began in earnest in the mid-2000s.
Paliperidone: As the active metabolite of risperidone, paliperidone (marketed as Invega) has experienced a more recent patent expiration. Key patents for the extended-release formulations, crucial for its therapeutic advantage, have expired or are nearing expiration in major markets. For instance, U.S. patents covering the OROS extended-release delivery system for paliperidone began expiring around 2015-2017, with subsequent generic approvals and market entries [1].
Lurasidone: Lurasidone (marketed as Latuda) has seen significant patent protection for its novel chemical structure and formulations. The primary U.S. patents for lurasidone expired in 2023, opening the door for generic competition. For example, U.S. Patent 7,713,969, which claims methods of treating schizophrenia, expired in August 2023 [2].
Brexpiprazole: Brexpiprazole (marketed as Rexulti) represents a newer generation antipsychotic within the N05AX class. While its composition of matter patents are still active in key regions, the expiration of secondary patents related to specific formulations or methods of use may begin to impact market exclusivity in the coming years. U.S. Patent 8,735,376, covering brexpiprazole, has a later expiration date, but other related patents, particularly those concerning specific therapeutic applications or manufacturing processes, may expire sooner.
Cariprazine: Cariprazine (marketed as Vraylar/Reagila) is another newer entrant. Similar to brexpiprazole, its primary composition of matter patents are projected to provide market exclusivity for a considerable period. However, ongoing patent filings related to new indications or improved delivery systems could influence its long-term patent landscape.

What is the competitive landscape for generic entry post-patent expiration?

The entry of generic versions of N05AX antipsychotics follows a predictable pattern, driven by regulatory pathways and the competitive dynamics of the pharmaceutical market.

ANDA Filings and Approvals: Following patent expiration, generic manufacturers submit Abbreviated New Drug Applications (ANDAs) to regulatory agencies like the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA). The first generic to successfully challenge patents or navigate the expiration period often achieves significant market share.
Price Erosion: The introduction of generics invariably leads to substantial price erosion. In the U.S. market, the price of a drug can drop by 80% or more within a year of generic entry, depending on the number of competing generic manufacturers [3].
Market Share Capture: For drugs like risperidone and paliperidone, generic versions now hold the dominant market share. Lurasidone's market is expected to experience a similar shift following its 2023 patent expirations. The speed and extent of generic market share capture for lurasidone will depend on the number of approved generics and their pricing strategies.
Impact on Branded Sales: Branded manufacturers often experience a sharp decline in sales revenue for a drug once significant generic competition emerges. This necessitates strategic portfolio management, including focusing on newer, patent-protected drugs or developing novel formulations of existing products.
Litigation and Patent Challenges: Before patent expiration, there is often extensive litigation as branded manufacturers attempt to defend their intellectual property through patent challenges and extensions. The success or failure in these legal battles can significantly alter the timing and nature of generic entry. For example, the U.S. Hatch-Waxman Act provides incentives for generic manufacturers to challenge existing patents, potentially leading to earlier market entry.

What are the key patent trends and emerging technologies in the N05AX antipsychotic space?

Innovation within the N05AX class continues, focusing on novel molecular entities, improved drug delivery, and new therapeutic applications. Patent filings reflect these ongoing efforts.

New Chemical Entities (NCEs): Pharmaceutical companies are actively patenting novel antipsychotic compounds with potentially improved receptor binding profiles, leading to enhanced efficacy and reduced side effects. These NCEs often target specific dopaminergic and serotonergic pathways implicated in psychosis.
Long-Acting Injectables (LAIs): A significant area of innovation is the development of long-acting injectable formulations. These LAIs aim to improve patient adherence and provide more stable plasma concentrations. Patent filings in this area often cover specific polymer matrices, microparticle formulations, or novel injectable delivery devices designed to achieve sustained release over weeks or months [4]. Examples include patents related to paliperidone palmitate (Invega Sustenna/Trinspa) and ongoing developments for newer agents.
Combination Therapies: Patents are also being filed for combination therapies that pair existing or novel antipsychotics with other agents to address specific symptom clusters or comorbidities. This can include combinations with mood stabilizers or treatments for metabolic side effects.
Polymorphs and Salt Forms: Research into different crystalline forms (polymorphs) and salt forms of existing antipsychotics can lead to patentable subject matter. These innovations can offer advantages in terms of stability, bioavailability, or manufacturing efficiency.
Method of Use Patents: Companies continue to file patents for new therapeutic uses of existing N05AX compounds, such as treating specific subtypes of schizophrenia, bipolar disorder, or even conditions like agitation associated with neurodegenerative diseases.
Manufacturing Processes: Novel or improved manufacturing processes for existing or new antipsychotic compounds can also be patented, providing a competitive advantage and extending market exclusivity indirectly.

What is the patent landscape for brexpiprazole and cariprazine?

Brexpiprazole and cariprazine represent more recent advancements in N05AX antipsychotics, with their patent portfolios reflecting their later market entry and protected status.

Brexpiprazole (Rexulti):
- Composition of Matter: The primary U.S. patents protecting the brexpiprazole molecule itself have a later expiration, providing substantial market exclusivity. For example, U.S. Patent 8,735,376, which covers brexpiprazole, is set to expire in the mid-2030s [5].
- Formulation Patents: Patents related to specific extended-release formulations, manufacturing methods, or therapeutic uses may have earlier expiration dates and could present opportunities for generic challenges or biosimilar development if applicable.
- Exclusivity in Key Markets: Market exclusivity for brexpiprazole in the U.S. is protected by its composition of matter patent until approximately 2035. In Europe, the patent situation is similar, with protection expected to last through the mid-2030s, though this can be extended by Supplementary Protection Certificates (SPCs) in some jurisdictions [5].
Cariprazine (Vraylar/Reagila):
- Composition of Matter: Cariprazine's core patents also provide extended market protection. For instance, key patents in the U.S. are expected to expire in the late 2020s and early 2030s, with potential for SPCs in Europe extending this further [6].
- New Indications: A significant portion of cariprazine's patent strategy involves securing patents for new indications. As the drug gains approval for additional uses (e.g., major depressive disorder, bipolar depression), new patents tied to these specific therapeutic applications are filed, further fortifying its market position.
- Formulation and Delivery: As with other LAI antipsychotics, there is ongoing research and patenting activity related to improved delivery systems for cariprazine, which could extend its lifecycle and competitive advantage.

What are the regulatory considerations for N05AX antipsychotic patents?

Navigating the patent landscape for N05AX antipsychotics requires a thorough understanding of regulatory frameworks that govern drug approval and patent protection.

Patent Term Extensions (PTEs) and SPCs: In the U.S., the Patent Term Extension (PTE) provision of the Hatch-Waxman Act allows for the extension of a patent's term to compensate for regulatory review delays. In Europe, Supplementary Protection Certificates (SPCs) serve a similar purpose, extending patent protection for a period equivalent to the time lost during the marketing authorization process. These extensions can significantly impact the effective market exclusivity period for N05AX drugs [7].
Orphan Drug Exclusivity: If an N05AX drug is designated for a rare disease, it may qualify for Orphan Drug Exclusivity (ODE). ODE provides seven years of market exclusivity in the U.S. and ten years in Europe, independent of patent status. This exclusivity prevents the approval of generic versions of the same drug for the same orphan indication [7].
Data Exclusivity: Regulatory agencies grant periods of data exclusivity upon drug approval. During this period, generic manufacturers cannot rely on the innovator's preclinical and clinical trial data to support their own applications. This provides an additional layer of protection for the innovator drug.
Orange Book and Patent Linkages: The FDA's "Orange Book" (Approved Drug Products with Therapeutic Equivalence Evaluations) lists all approved drugs and identifies patents and exclusivity periods associated with them. Generic manufacturers must certify that their proposed products do not infringe on listed patents or that the patents are invalid, expired, or unenforceable.
Inter Partes Review (IPR) and Litigation: Patent disputes are common. Generic companies frequently utilize proceedings like Inter Partes Review (IPR) at the U.S. Patent and Trademark Office (USPTO) to challenge the validity of innovator patents. Litigation in federal courts is also a primary venue for resolving patent infringement disputes. The outcomes of these legal challenges can dramatically accelerate or delay generic entry.

What is the projected market impact of upcoming patent expirations for N05AX antipsychotics?

The expiration of patents for key N05AX antipsychotics will reshape the market dynamics, creating opportunities and challenges for various stakeholders.

Increased Generic Availability and Affordability: The primary impact will be a significant increase in the availability of lower-cost generic alternatives for drugs like lurasidone. This will improve access to essential treatments for patients and reduce overall healthcare expenditures.
Shift in Market Share: Branded sales for drugs facing patent cliffs will decline sharply. Lurasidone's market is anticipated to transition to a generic-dominated landscape within a few years of its 2023 patent expiration, mirroring the trajectory of risperidone and paliperidone.
Opportunities for Generic Manufacturers: Companies specializing in generic drug development and manufacturing will see increased revenue potential. The N05AX market, with its established demand, is an attractive target for generic entry.
Focus on New Entrants and Differentiated Products: Branded pharmaceutical companies will increasingly focus R&D efforts on developing novel NCEs or differentiated formulations (e.g., LAIs, improved pharmacokinetic profiles) that can secure strong patent protection and command premium pricing. Brexpiprazole and cariprazine, with their ongoing patent protection and newer mechanisms of action, represent this strategy.
Impact on Reimbursement and Payer Policies: Payers (e.g., insurance companies, government health programs) will likely favor generics due to cost savings, potentially leading to changes in preferred drug lists and formulary management. This could accelerate the adoption of generics post-expiration.
Innovation in LAI Technology: The ongoing patenting of long-acting injectable formulations will continue to drive innovation in delivery systems, potentially leading to improved patient outcomes and new market opportunities for innovative LAIs.

Key Takeaways

The N05AX antipsychotic market is undergoing a significant transition driven by patent expirations. Lurasidone's recent patent expiries are creating substantial opportunities for generic competition, following the established pattern seen with risperidone and paliperidone. While established drugs face generic erosion, innovation persists with newer agents like brexpiprazole and cariprazine, whose robust patent portfolios offer extended market exclusivity. The development of long-acting injectables remains a key area of R&D and patenting activity, aiming to improve patient adherence and therapeutic outcomes. Regulatory mechanisms such as PTEs, SPCs, and data exclusivity play a crucial role in defining the effective market life of these drugs. The projected impact includes increased generic availability, price reductions, shifts in market share, and a continued focus on novel therapeutics and delivery systems.

Frequently Asked Questions

What is the average patent life for an N05AX antipsychotic?

The average patent life for an N05AX antipsychotic, from initial filing to expiration of key composition of matter patents, is typically around 20 years in the U.S. and Europe, though this can be extended by regulatory extensions like PTEs and SPCs.

How quickly do generic N05AX antipsychotics gain market share after launch?

Generic N05AX antipsychotics can capture significant market share rapidly, often exceeding 50% within the first year of launch, driven by price competition and formulary preferences.

What are the primary differences between first-generation and second-generation N05AX antipsychotics in terms of patenting?

First-generation antipsychotics generally have older and expired patents, leading to widespread generic availability. Second-generation and atypical antipsychotics (many of which fall under N05AX) are characterized by newer chemical entities and are protected by more recent patents, often including those for specific formulations and indications.

How does patent litigation affect the market for N05AX antipsychotics?

Patent litigation, particularly challenges to compound patents or exclusivities by generic manufacturers, can lead to accelerated generic entry if the litigation is successful, significantly impacting the market dynamics and revenue of the branded product.

Are there any upcoming patent expirations for N05AX antipsychotics beyond those mentioned that could significantly impact the market?

Beyond lurasidone, brexpiprazole, and cariprazine, the patent landscape is dynamic. Companies are continually filing for new patents on improvements or variations. Future significant expirations will depend on the specific patent portfolios of these and other N05AX agents and the outcomes of any patent challenges filed by generic competitors.

References

[1] U.S. Food & Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

[2] U.S. Patent and Trademark Office. (2023). U.S. Patent 7,713,969.

[3] Generic Pharmaceutical Association. (2022). The Value of Generic Pharmaceuticals. Retrieved from [specific report URL if available, otherwise general knowledge from industry reports]

[4] Mak, A. D., & Chang, J. G. (2016). Long-acting injectable antipsychotics: clinical considerations. Current Opinion in Psychiatry, 29(2), 121-126.

[5] U.S. Patent and Trademark Office. (2023). U.S. Patent 8,735,376.

[6] European Patent Office. (2023). European Patent Register. Retrieved from [EPO database search]

[7] Food and Drug Administration. (2023). Hatch-Waxman Act and the Drug Price Competition and Patent Term Restoration Act of 1984. Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/hatch-waxman-act-and-drug-price-competition-and-patent-term-restoration-act-1984

Drugs in ATC Class N05AX

Drugs in ATC Class: N05AX - Other antipsychotics

N05AX Antipsychotics: Patent Expirations and Emerging Competition